✦ LIBER ✦

Clinical Relevance of Urokinase-Type Plasminogen Activator, Its Receptor, and Its Inhibitor Type 1 in Endometrial Cancer

✍ Scribed by Coşkun Tecimer; David L. Doering; L.Jane Goldsmith; John S. Meyer; Gazi Abdulhay; James L. Wittliff

Book ID: 112248320
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 67 KB
Volume: 80
Category: Article
ISSN: 0090-8258
DOI: 10.1006/gyno.2000.6015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Urokinase and plasminogen activator inhi

Urokinase and plasminogen activator inhibitor type 2 in endometrial cancer

✍ N. Gleeson; R. Gonsalves; J. Bonnar 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 321 KB

Role of urokinase-type plasminogen activ

Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer

✍ E. Steiner; K. Pollow; D. Hasenclever; W. Schormann; M. Hermes; M. Schmidt; A. P 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 799 KB

Expression of urokinase-type plasminogen

Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma

✍ Li Zhou; Yoshitake Hayashi; Takashi Itoh; Weiping Wang; Jing an Rui; Hiroshi Ito 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 575 KB

31 Basic fibroblast growth factor, uroki

31 Basic fibroblast growth factor, urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 in lung cancer cells

📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 114 KB

Clinical relevance of urokinase-type pla

Clinical relevance of urokinase-type plasminogen activator and its inhibitor type 1 (PAI-1) in squamous cell carcinoma of the uterine cervix

✍ LC Horn; S Pippig; G Raptis; U Fischer; U Köhler; B Hentschel; R Martin 📂 Article 📅 2002 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 86 KB

Clinical relevance of urokinase plasmino

Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma

✍ Rainer Hofmann; Antonie Lehmer; Markus Buresch; Rudolf Hartung; Kurt Ulm 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 559 KB

## BACKGROUND. Urokinase plasminogen activator (u-PA) plays a key role in the metastatic process by promoting plasmin mediated tissue degradation. Metastatic cell invasion requires localized proteolysis, which may be directed by u-PA receptor. The binding of u-PA and PAI-1 to the u-PA-receptor may